Baxter Biopharma Solutions Sterile Manufacturing Agreement for Novavax Covid-19 Vaccine Announced
Baxter International has announced that Baxter BioPharma Solutions has entered into an agreement to provide...
Optimising lyophilisation cycle times and improving stability for complex injectables is a critical component of parenteral product development.
With this understanding, BioPharma Solutions established the Lyophilization Center of Excellence (LCOE), a resource centre to focus on the development of high-quality freeze-drying. Distinguished scientists and educators Dr Steven Nail and Wendy Saffel-Clemmer lead BioPharma’s team of scientists to assist with modifications and formulas to maximise the potential of lyophilised products.
Staffed by 18 scientists with an average experience of 18 years, the centre allows clients to feel confident knowing their molecule is in goods hands.
Baxter’s approach to freeze-dry cycle development products advantages over traditional cycle development, including:
BioPharma Solutions’ facility in Bloomington, Indiana, is home to the LCOE, which is staffed by scientists with expertise in parenteral product formulation, process and analytical development.
Lyophilisation tools and techniques include:
The LCOE offers:
Quick facts about the LCOE staff:
Baxter International has announced that Baxter BioPharma Solutions has entered into an agreement to provide...
Global leader in sterile medication production and delivery, Baxter International, is pleased to announce a...
Baxter International Inc representatives globally are rising to the call and making a difference in...
The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers...